NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS ) remains under the radar but has one of the best late-stage cardiovascular pipelines in biotech. Although most attention on the market today is focused on GLP-1s and their potential impactI have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and investing in disruptive technologies and forward-thinking enterprises. My approach is a mix of fundamental analysis an ...